Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
 

Search in our Online Store

Antibodies
Filter     Order     Display # 
Date Item Title
02 Jun 2006 Life Science Pharmaceuticals Acquires Three Clinical Stage Monoclonal Antibody Programs From the Ludwig Institute for Cancer Research
02 Jun 2006 Halozyme Therapeutics Presents Preclinical and Pharmacokinetic Data on the Subcutaneous Delivery of Antibodies With Enhanze Technology at the 2006 IBC Antibody Conference
01 Jun 2006 EvoGenix Announces Antibody Collaboration with CSL
01 Jun 2006 Results of TNX-355 Combination Study Published in Antimicrobial Agents and Chemotherapy
31 May 2006 KaloBios Collaborates to Engineer Human Antibody Therapeutic Drugs
31 May 2006 Millennium Announces MLN1202 Fully Met Primary Endpoint in Phase II Clinical Study of Patients at High Risk for Atherosclerosis
31 May 2006 Nabi Biopharmaceuticals Provides Regulatory Update on Hepatitis B Liver Transplant Programs
26 May 2006 Final report on TGN1412 clinical trial
26 May 2006 Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line Metastatic Breast Cancer
25 May 2006 Progenics Broadens Collaboration with Seattle Genetics for Prostate Cancer Therapy; Positive Preclinical Findings on PSMA Antibody-Drug Conjugate Published in Clinical Cancer Research Journal
25 May 2006 Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing
25 May 2006 New Data for Nuvion(R) Presented at Digestive Disease Week Conference
24 May 2006 XOMA and Schering-Plough Establish Collaboration for Therapeutic Antibody Discovery and Development
24 May 2006 Herceptin approved in Europe for early use in HER2-positive breast cancer
24 May 2006 Genmab Initiates Humax-CD20 CLL Pivotal Study
23 May 2006 First Patient Dosed in Phase 1 Trial of Tanox's TNX-650
23 May 2006 Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
23 May 2006 Dyax Corp. and ICOS Corporation Enter Into License Agreement for Discovery of Therapeutic Antibodies
23 May 2006 New CIMZIA™ Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
23 May 2006 Promising Pivotal Phase III Data Show Abbott's HUMIRA® (adalimumab) Maintained Clinical Remission in Patients with Crohn's Disease Through One Year
22 May 2006 Zenyth Receives Fourth Milestone Payment From Merck & Co., Inc. For Asthma Treatment
20 May 2006 FDA Approves Remicade for Children with Crohn’s Disease
17 May 2006 XOMA Establishes Development and Manufacturing Relationship with Taligen; XOMA to utilize its Bacterial Cell Expression Technology to Manufacture Novel Anti-Inflammatory Therapeutic for Clinical Trials
17 May 2006 MorphoSys and Schering-Plough Sign R&D Agreement
16 May 2006 AMG 714 Data To Be Presented At EULAR Conference
15 May 2006 ALEXION Pharmaceuticals’ Antibody Therapy Shown Effective in Model for Severe Allergic Asthma
12 May 2006 Strategic alliance with Merck to develop monoclonal antibodies to treat S. aureus infections
11 May 2006 Caprion Receives FDA Fast Track Designation for Shigamabs Clinical Program
11 May 2006 Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer
10 May 2006 UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
09 May 2006 Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
06 May 2006 U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.
05 May 2006 ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech; Companies Also Amend 2000 Agreement for TAP Compounds Targeting HER2, Potentially Providing Increased Royalties and Milestones to ImmunoGen
04 May 2006 Seattle Genetics Reports on SGN-30 Cutaneous ALCL Phase II Clinical Trial at the Society of Investigative Dermatology Meeting
02 May 2006 Tanox Reports 48-Week Results from TNX-355 Phase 2 Clinical Trial
28 Apr 2006 Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion From European Medicines Agency for the Treatment of Ankylosing Spondylitis
28 Apr 2006 CHMP Issues Positive Opinion for TYSABRI® as a Treatment for Relapsing-Remitting Multiple Sclerosis
28 Apr 2006 UCB Submits Marketing Authorisation Application in Europe for CIMZIA (TM), a New Crohn’s Disease Therapy
27 Apr 2006 YM BioSciences' partner, Oncoscience AG, commences patient treatment in phase III trial in Germany with nimotuzumab
27 Apr 2006 XOMA and AVEO Announce Agreement to Apply Human Engineering™ Technology to AV-299, AVEO’s
25 Apr 2006 Chugai Pharmaceutical Files New Drug Application for Anti-tumor Agent Bevacizumab
25 Apr 2006 Epratuzumab for Immunotherapy of Lupus Results Published
21 Apr 2006 BioInvent and Immusol to collaborate on antibody therapeutic for macular degeneration
20 Apr 2006 MedImmune Licenses Elusys Therapeutics' Technology for Use in Developing New Therapies Targeting Infectious Disease
14 Apr 2006 MedImmune Begins Dosing of Lupus Patients in Phase 1 Clinical Trial
12 Apr 2006 Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
12 Apr 2006 Biolex Therapeutics Announces Expansion Of Medarex Collaboration
11 Apr 2006 Additional Preclinical and Clinical Data Indicate Abegrin(TM) May Offer Three-Pronged Approach to Cancer Therapy
11 Apr 2006 InNexus Biotechnology and Affimed Therapeutics AG to Collaborate; Will Use SuperAntibody Technology to Target Multiple Cancers
07 Apr 2006 New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis
 
<< Start < Prev 21 22 23 24 Next > End >>
Results 1001 - 1050 of 1155

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics